

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

accept change(s) to the agreed paediatric investigation plan (MHRA-100078-PIP01-21-M03)  
MHRA-100078-PIP01-21-M05

### **Scope of the Application**

#### **Active Substance(s)**

AVIBACTAM SODIUM; AZTREONAM

#### **Condition(s)**

Treatment of infections caused by aerobic gram-negative bacteria

#### **Pharmaceutical Form(s)**

Powder for concentrate for solution for infusion

#### **Route(s) of Administration**

INTRAVENOUS USE

#### **Name / Corporate name of the PIP applicant**

Pfizer Limited

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, Pfizer Limited submitted to the licensing authority on 25/11/2025 09:00 GMT an application for a Modification

The procedure started on 08/12/2025 13:04 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100078-PIP01-21-M05

Of 07/04/2026 07:01 BST

On the adopted decision for AVIBACTAM SODIUM; AZTREONAM (MHRA-100078-PIP01-21-M05) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for AVIBACTAM SODIUM; AZTREONAM, Powder for concentrate for solution for infusion , INTRAVENOUS USE .

This decision is addressed to Pfizer Limited, Ramsgate Road, Sandwich, Kent, UNITED KINGDOM, CT139NJ

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Not applicable

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of infections caused by aerobic gram-negative bacteria

#### 2.2 Indication(s) targeted by the PIP:

Treatment of infections caused by aerobic gram-negative bacteria in patients with limited therapeutic options

### 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age

### 2.4 Pharmaceutical Form(s):

Powder for concentrate for solution for infusion

### 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of age-appropriate formulation(s) for parental use or fixed-dosed combination (FDC) of ATM/AVI at a ratio to be determined based on study 4 and study 5 in paediatric patients from birth to less than 18 years of age.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	2	Study 2 (C3601008) A randomised, open-label (with a blinded observer), active-comparator study of IV ATM/AVI in patients from 9 months of age to less than 18 years of age who are hospitalised due to complicated urinary tract infection (cUTI), complicated intra-abdominal infection (cIAI), hospital-acquired bacterial pneumonia (HABP)/ ventilator associated bacterial pneumonia (VABP), blood stream infections (BSI), or sepsis caused (confirmed or suspected) by gram-negative organisms. Study 3 (C3601010) An open-label, single arm, two-part study (Part A – single dose PK and Part B – multiple dose) study of IV ATM/AVI in patients from birth to less than 9 months of age who are hospitalised due to cUTI, cIAI, HABP/VABP, BSI, or sepsis caused (confirmed

		or suspected) by gram-negative organisms.
<b>Extrapolation, Modeling &amp; Simulation Studies</b>	2	Study 4 Population PK-PD modelling and simulation study to evaluate the PK-PD relationship of IV ATM/AVI in paediatric patients from 9 months to less than 18 years of age. Study 5 Population PK-PD modelling and simulation study to evaluate the PK-PD relationship of IV ATM/AVI in paediatric patients from birth to less than 9 months of age.
<b>Other Studies</b>	0	Not applicable.
<b>Other Measures</b>	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	Yes
<b>Date of completion of the paediatric investigation plan:</b>	29/02/2028
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes